Your question is Valuing Early-Stage Bioplatforms. Take a moment with it on the right.
Talk me through your thinking if you like. When you're confident, submit your answer and I'll grade it like a real screen (7/10 or better passes).
How do you approach valuing an early-stage bioplatform technology that does not yet have a clinical asset?